Quantum BioPharma Featured in CTV News Investigation on Stock Manipulation Allegations
TL;DR
Quantum BioPharma's $700 million lawsuit and $7 million reward offer against market manipulation could create significant shareholder value if successful.
Quantum BioPharma alleges stock spoofing by CIBC and RBC in a lawsuit, with a $7 million reward for information leading to judgment or settlement.
Quantum BioPharma's commitment to advancing MS research through Lucid-MS aims to improve treatments for neurodegenerative disorders and protect shareholder interests.
CTV News' W5 program featured Quantum BioPharma's allegations of stock spoofing, highlighting rising market manipulation cases in Canada.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was the focus of CTV News' W5 program, which aired Part Three of its investigative series examining the company's allegations of stock spoofing tied to its USD $700 million lawsuit against CIBC and RBC. The episodes detail rising market-manipulation cases in Canada and highlight Quantum's call for accountability, with CEO Zeeshan Saeed reaffirming the company's commitment to defending shareholders and advancing MS research.
The company's Co-Executive Chair Anthony Durkacz has offered up to USD $7 million for information leading to a final judgment or settlement in related litigation, demonstrating the seriousness with which Quantum BioPharma is pursuing these allegations. This legal action comes at a time when market manipulation cases are reportedly increasing in Canada, making the company's situation particularly noteworthy for investors and regulators alike.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
The company also maintains strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. Quantum BioPharma invented unbuzzd(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc., with Quantum retaining ownership of 20.11% of Unbuzzd Wellness Inc. as of March 31, 2025. The agreement includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum BioPharma total $250 million, after which the royalty drops to 3% in perpetuity.
For investors seeking additional information, the latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The press release about the CTV News feature can be viewed at https://ibn.fm/OsuC0. This coverage comes through InvestorWire, a specialized communications platform that is one of 70+ brands within the Dynamic Brand Portfolio at IBN that delivers advanced wire-grade press release syndication for private and public companies and the investment community.
The implications of this investigation extend beyond Quantum BioPharma's specific case, potentially affecting how Canadian markets address stock manipulation allegations and how biopharmaceutical companies navigate legal challenges while continuing their research missions. The company's dual focus on pursuing legal action while advancing medical research represents a complex balancing act that could influence investor confidence in similar firms facing regulatory or legal challenges.
Curated from InvestorBrandNetwork (IBN)
